Comment
Author: Admin | 2025-04-28
Dosing & UsesAdultPediatricDosage Forms & Strengths tablet (Evekeo): Schedule II 5mg 10mg extended-release oral tablets (Dyanavel XR): Schedule II 5mg 10mg 15mg 20mg extended-release oral suspension (Dyanavel XR): Schedule II 2.5mg/mL extended-release oral disintegrating tablet (Adzenys XR-ODT): Schedule II 3.1mg 6.3mg 9.4mg 12.5mg 15.7mg 18.8mg Narcolepsy 5-60 mg/day PO in divided doses depending on the individual patient response Administer at the lowest effective dose; individually adjust dosage Obesity Indicated as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy (eg, repeated diets, group programs, and other drugs) Usual dosage is up to 30 mg daily, taken in divided doses of 5-10 mg, 30-60 minutes before meals Administer at the lowest effective dose; individually adjust dosage Attention Deficit Hyperactivity Disorder Indicated for attention deficit hyperactivity disorder (ADHD) in adolescents and adults Adzenys XR-ODT: 12.5 mg PO qAM Dyanavel XR: 2.5-5 mg PO qAM; may increase by 2.5 -10 mg/day q4-7days; not to exceed 20 mg/day Evekeo: 5 mg PO qDay or q12hr; may increase by 5 mg qWeek until optimal response is obtained; not to exceed 40 mg/day Dosage Modifications Equivalent doses of Adzenys XR-ODT and Adderall XR Adzenys XR-ODT 3.1 mg (2.5 mL): Adderall XR 5 mg Adzenys XR-ODT 6.3 mg (5 mL): Adderall XR 10 mg Adzenys XR-ODT 9.4 mg (7.5mL): Adderall XR 15 mg Adzenys XR-ODT 12.5 mg (10 mL): Adderall XR 20 mg Adzenys XR-ODT 15.7 mg (12.5 mL): Adderall XR 25 mg Adzenys XR-ODT 18.8 mg (15 mL): Adderall XR 30 mg Concomitant use of extended-release amphetamines with other medications Do not administer concomitantly or within 14 days after discontinuing MAO inhibitors Coadministration of and gastrointestinal alkalinizing agents should be avoided See Warnings Dosing Considerations Do not substitute for other amphetamine products on a mg-per-mg basis, because of different amphetamine base compositions and differing pharmacokinetic profiles Before initiating Assess for presence of cardiac disease (ie, perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) Assess risk of abuse before prescribing, and monitor for signs of abuse and dependence while on therapy; maintain careful prescription records, educate patients about abuse, monitor for signs of abuse and overdose, and periodically re-evaluate the need for use Dosage Forms & Strengths tablet (Evekeo): Schedule II 5mg 10mg oral disintegrating tablet (Evekeo ODT): Schedule II 5mg 10mg 15mg 20mg extended-release oral tablets (Dyanavel XR): Schedule II 5mg 10mg 15mg 20mg extended-release oral suspension (Dyanavel XR): Schedule II 2.5mg/mL extended-release oral disintegrating tablet (Adzenys XR-ODT): Schedule II 3.1mg 6.3mg 9.4mg 12.5mg 15.7mg 18.8mg Attention Deficit Hyperactivity Disorder Evekeo 3-5 years: 2.5 mg PO qDay initially; may increase daily dose by 2.5-mg increments
Add Comment